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Abstract
Purpose: Radiation therapy dose escalation using stereotactic body radiation therapy may significantly improve both local control
(LC) and overall survival (OS) for patients with inoperable pancreas cancer. However, ablative dose cannot be routinely offered
because of the risk of causing severe injury to adjacent normal organs. Stereotactic magnetic resonance (MR)-guided adaptive
radiation therapy (SMART) represents a novel technique that may achieve safe delivery of ablative dose and improve long-term
outcomes.
Methods and Materials: We performed a single institution retrospective analysis of 35 consecutive pancreatic cancer patients treated
with SMART in mid-inspiration breath hold on an MR-linear accelerator. Most had locally advanced disease (80%) and received
induction chemotherapy (91.4%) for a median 3.9 months before stereotactic body radiation therapy. All were prescribed 5 fractions
delivered in consecutive days to a median total dose of 50 Gy (BED10 100 Gy10), typically with a 120% to 130% hotspot. Elective nodal
irradiation was delivered to 20 (57.1%) patients. No patient had fiducial markers placed and all were treated with continuous
intrafraction MR visualization and automatic beam triggering.
Results: With median follow-up of 10.3 months from SMART, acute (2.9%) and late (2.9%) grade 3 toxicities were uncommon. One-
year LC, distant metastasis-free survival, progression-free survival, cause-specific survival, and OS were 87.8%, 63.1%, 52.4%, 77.6%,
and 58.9%, respectively.
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Conclusions: To our knowledge, this is the first report of 5-fraction pancreas SMART delivered on an MR-linear accelerator. We
observed minimal severe treatment-related toxicity and encouraging early LC. Prospective confirmation of feasibility and long-term
clinical outcomes of dose intensified SMART is warranted.
 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Pancreas cancer has a dismal prognosis with 5-year
overall survival (OS) of <5% despite aggressive man-
agement.1 Although the effect of nonablative radiation
therapy (RT) on OS for locally advanced pancreas cancer
(LAPC) continues to be debated, randomized data
demonstrate improved local control (LC) with chemo-
radiation versus chemotherapy alone.2 This is meaningful
as up to one-third of patients may die of local progression
rather than distant metastases.3
A growing body of literature suggests that escalation
of the biologically effective dose (BED) may improve LC,
which may improve OS for inoperable patients.4e10
Furthermore, published guidelines recommend that dose
escalation be considered if appropriate resources, such as
motion management and daily image guidance are
available to ensure safety.11 However, delivery of ablative
dose (eg, [BED10] 100 Gy10) to the majority of gross
disease using computerized tomography (CT) guidance is
not attempted for most patients owing to the proximity of
tumor to luminal gastrointestinal (GI) organs at risk
(OAR).12
Magnetic resonanceeguided radiation therapy
(MRgRT) represents a novel solution to deliver ablative
dose to larger volumes of gross disease regardless of
proximity to OARs in up to 5 fractions owing to several
key features: (1) superior soft tissue visualization
compared with CT,13 (2) real-time continuous intra-
fraction assessment of internal structures, (3) automatic
beam gating based on target position, and (4) daily on-
table adaptive replanning.14e16 A multi-institutional
retrospective analysis of stereotactic MR-guided adap-
tive radiation therapy (SMART) using cobalt-60 (Co-60)
demonstrated encouraging survival with no high-grade
toxicity among patients who received dose escalation.5
These outcomes are supported by a recent single institu-
tion report of 5-fraction SMART, mostly delivered using
Co-60.17
The first MR-linear accelerator (LINAC) became clini-
cally operational in 2017, offering improved dosimetry
with multifield intensity modulated radiation therapy
(IMRT) compared with Co-60 and achieving comparable
plan quality to a conventional c-arm linac.18,19 Higher dose
conformality made feasible by the MR-LINAC increases
the potential for higher target doses previously not achieved
with the first-generation MRgRT Co-60 machines.
To the best of our knowledge, we report the first
clinical experience of 5-fraction SMART for initially
inoperable pancreas cancer exclusively on an MR-
LINAC.
Methods and Materials
Patient details and clinical evaluation
After obtaining institutional review board approval, a
retrospective analysis was performed of 35 consecutive
nonmetastatic patients with biopsy-proven pancreas
adenocarcinoma who were treated with SMART on the
ViewRay MRIdian Linac (Oakwood Village, OH) be-
tween October 2018 and November 2019 at a single
institution.
No minimum distance between tumor and GI luminal
organs was required for patients to be considered for
SMART. Duodenal invasion based on endoscopic eval-
uation was a contraindication. Patients were offered
SMART regardless of tumor size or number of involved
regional lymph nodes. No patient had previously received
abdominal RT.
All underwent endoscopic ultrasound and CT scans of
the chest, abdomen, and pelvis for initial staging. The
majority also had either diagnostic MRI abdomen or
positron emission tomography scans. Staging and resect-
ability was determined according to the National
Comprehensive Cancer Network guidelines.20
Nearly all (91.4%) received induction chemotherapy
for a median 3.9 months (range, 2-12.3 months) before
SMART, most commonly with FOLFIRINOX (5-
fluorouracil, irinotecan, leucovorin, oxaliplatin; 60%)
and otherwise gemcitabine-based regimens. Three pa-
tients did not receive induction chemotherapy because of
suboptimal performance status. No patient received con-
current chemotherapy.
RT treatment planning and delivery
Simulation was performed without delay for fiducial
marker placement because MR guidance provides direct
visualization of the tumor obviating the need for a sur-
rogate marker. Patient geometry was supine and typically
with both arms down at sides to improve patient comfort
and beam angles were avoided that would treat through
the arms.18 Simulation included a planning 0.35 T mid-
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inspiration breath hold, balanced steady-state free pre-
cession sequence (TrueFISP) MR scan (17-25 sec) ac-
quired on the MRIdian Linac immediately followed by a
planning CT scan. No immobilization device was used
because daily 3-dimensional and 2-dimensional MRI was
performed for inter and -intrafraction motion manage-
ment, respectively.
The target and OAR contours were delineated on the
TrueFISP MR simulation scan and exported to the
MRIdian treatment planning system. The simulation CT
was also exported to MRIdian treatment planning system
and deformably registered to the simulation MR scan for
electron density information for dose calculation pur-
poses. For some cases, bulk density assignment to the
vertebral bodies as bone, external as water, and any
abdominal gas as air was used to account for changes in
anatomy between simulation CT and MRI. Intravenous or
oral contrast was not given because the tumor and normal
anatomy were well-visualized on the MR simulation scan
and diagnostic imaging was fused as needed to define the
target volumes.
The MRIdian Linac uses a step-and-shoot IMRT
treatment delivery as has been previously described.21,22
Table 1 lists the OAR constraints used for initial plan-
ning and on-table adaptive replanning. A 12 to 18 beam,
step-and-shoot IMRT plan was created with a 2.0 mm3
resolution Monte Carlo dose calculation and magnetic
field corrections. All plans underwent a measurement-
based verification quality assurance using criteria of 2%/
2 mm distance-to-agreement for a g-analysis pass rate of
90%.
Gross target volume (GTV) was defined as gross tumor
within the pancreas and involved locoregional lymph
nodes as seen on diagnostic imaging and simulation CT or
MR scans; this was uniformly expanded by 3 mm to
create the planning target volume (PTV). A 3 to 5 mm
expansion of the GI OARs was performed to create
planning organ at risk volumes (PRVs). Any overlapping
portion of the GTV or PTV by the PRVs was strictly
constrained to 35 Gy to facilitate meeting OAR con-
straints and the remainder was dose-escalated to 50 Gy
(n Z 30; 85.7%) although several patients in our early
experience were prescribed 40 Gy (n Z 1; 2.9%) or 45
Gy (n Z 4; 11.4%) owing to initial uncertainty about
patient tolerability. Grossly involved lymph nodes were
prescribed the same dose as the primary tumor. The
dosimetric hotspot was optimized to be 120% to 130%
of the prescription dose and encompassed as much of the
PTV outside of the PRV as possible provided that OAR
constraints were met.
Real-time tissue tracking on sagittal image acquisition
every 250 ms was performed to automatically gate the
treatment delivery.23 The tracking region of interest was
defined daily from the GTV. Beam delivery was auto-
matically paused when >3% to 5% of the tracking region
of interest was displaced by >3 mm from its prescribed
location. Treatment was delivered for all patients in mid-
inspiration breath hold to optimize duty cycle
efficiency.24
Our initial practice was to treat gross disease only and
not elective nodal regions. After it was apparent that
treatment was tolerated well we eventually adopted the
routine use of elective nodal irradiation (ENI); this deci-
sion was influenced by patterns of failure data indicate
that ENI may reduce locoregional failures.6,25 As such,
ENI was delivered to the more recently treated 20 patients
(57.1%) and the electively treated region gradually
evolved to include a 5 to 10 mm radial expansion around
the celiac axis, superior mesenteric vein, and superior
mesenteric artery; up to the proximal 10 to 15 mm of
these vessels was also included. Instead of routinely
creating a clinical target volume, electively treated regions
were typically included within the GTV to minimize the
number of structures, expedite daily adaptive replanning,
and reduce time patients were in the treatment unit. As
such, electively treated regions were usually prescribed
the same dose as gross disease.
On-table adaptive workflow
Our on-table adaptive MRgRT workflow was based on
prior publications.15,26 Target volumes were rigidly
registered from the simulation MR to the daily volumetric
MR scan frame of reference and OARs underwent
deformable registration. The target volumes were not
modified because a change in gross tumor was not ex-
pected over the course of 5 fractions. OAR contours
within 3 cm radially of the PTV and 2 cm cranial or
caudal of the PTV were edited to reflect the anatomy of
the day (Fig. 1).15 The optimization target volume
assigned to the ablative prescription dose was updated to
exclude the GI PRVs of the day.
After recontouring structures based on the current
day’s MRI anatomy, calculation of the initial plan using
the current day’s contours was performed to understand
the predicted dose to targets and OARs. A predicted plan
was created for all 175 fractions because visual
Table 1 Organ at risk constraints for 5-fraction pancreas
stereotactic magnetic resonance image guided adaptive ra-
diation therapy
Organ at risk Dose constraint
Stomach, duodenum, small bowel V35 <0.5 mL
V40 <0.03 mL
Large bowel V38 <0.5 mL
V43 <0.03 mL
Kidneys Mean <10 Gy
Liver Mean <15 Gy
Spinal cord V25 <0.03 mL
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assessment of the daily images alone has been shown to
not be adequate for decision making about the indication
for adaptation.26 Plan reoptimization was performed to
meet dose constraints or improve target coverage; priority
was always to ensure that OAR constraints were met even
at the expense of target coverage. If all constraints were
met on the predicted dose and the target coverage was not
improved for the reoptimized plan, then the predicted plan
was used. Plan prediction and reoptimization did not ac-
count for prior dose delivered. Before treatment, plan fi-
delity was verified through a secondary Monte Carlo
quality assurance dose calculation.
Follow-up and outcomes assessment
Patients were followed with CT or MRI scans and
CA19-9 assessment starting 4 to 6 weeks after SMART
and every 2 to 3 months thereafter, or sooner as clinically
indicated. No patient was prescribed a proton pump in-
hibitor after SMART. Chemotherapy was typically not
started after SMART unless there was evidence of disease
progression.
Toxicity was defined according to the Common Ter-
minology Criteria for Adverse Events (CTCAE version
5.0). We evaluated the highest grade toxicity experienced
by each patient, with acute toxicity being considered to
have occurred during or within 90 days after the start of
SMART. All toxicity was prospectively evaluated upon
each clinic encounter and recorded in the patient’s elec-
tronic medical record.
Statistical analysis
Study data were collected and managed using
Research Electronic Data Capture27 and statistical ana-
lyses were performed using SAS (version 9.4, SAS
Institute, Cary, NC). Wilcoxon rank-sum test was used to
compare time from initial setup to treatment delivery
completion, time to deliver treatment, and in-room time
between initial and more recently treated patients. Follow-
up time was determined from the first day of SMART
until the date of last patient contact or death. All clinical
outcomes were assessed from the date of SMART initi-
ation and were determined using the Kaplan-Meier
method. LC was defined as lack of progression of the
primary pancreas tumor or within regional lymph nodes
according to Response Evaluation Criteria in Solid Tu-
mors 1.1 criteria, distant metastasis-free survival was
Figure 1 Target volumes (top row) and isodose lines (bottom row) for a pancreas cancer patient prescribed 50 Gy in 5 consecutive
fractions with daily magnetic resonance image guidance and on-table adaptive replanning. Abbreviations: OAR organs at risk; PTV Z
planning target volume.
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defined as time to distant recurrence, and progression-free
survival (PFS) was defined as the time from first delivered
SMART fraction to local recurrence, distant recurrence,
or death. Cause-specific survival (CSS) was defined as the
time to death owing to pancreas cancer whereas OS was
defined as the time to death from any cause.
Results
Table 2 describes patient and tumor characteristics. A
total of 35 consecutive patients were evaluated with me-
dian age of 67 years (range, 34-89 years), most frequently
with tumors in the head of pancreas (88.6%) and with
locally advanced disease (80%). Median CA19-9 at initial
diagnosis was 102.5 U/mL (range, 0.9-1517.5 U/mL) and
this decreased to a median of 47.0 U/mL (range, 1.2-
216.6 U/mL) at a median 5 weeks before SMART.
The median follow-up for all patients was 10.3 months
(range, 2.2-17.9) and 12.5 months for 21 patients (60%)
who were alive at time of analysis (range, 4.5-14.2). All
patients had at least 3 months of follow-up except for one
who died 2.2 months after SMART; 15 patients (42.9%)
were followed for at least 12 months from SMART.
Treatment planning and delivery
The median GTV and PTV for all patients were 65.6
mL and 99.8 mL, respectively. The median GTV and
PTV of patients who did not receive ENI were 28.44 mL
(range, 6.1-66.9 mL) and 43.2 mL (range, 11.3-68.6 mL),
respectively, and for patients treated with ENI, they were
102.0 cc (range, 55.1-284.3 mL) and 141.0 mL (range,
77.1-368.1 mL), respectively.
The median number of fractions that met criteria for
adaptive replanning was 5 (range, 1-5). Across all frac-
tions, 169 (96.6%) were adapted online and all 5 fractions
were adapted online for 33 patients (94.3%).
Table 3 displays the target volume coverage in total
dose for the initial plan on the simulation anatomy versus
on-table adaptive plans on the daily anatomy. Ablative
dose was delivered to most of the target volumes on the
initial plans as demonstrated by the median GTV and
PTV D80 (52.5 Gy, 46.2 Gy) and D90 (50.8 Gy, 39.8 Gy),
respectively. Furthermore, the prescribed dose covered a
median 80.5% of the PTV on the initial plans. Despite the
need to adapt most fractions we were able to maintain
excellent high dose coverage (median D80: 49.6 Gy, 44.7
Gy and median D90: 47.5 Gy, 40.5 Gy) to most of the
GTV and PTV, respectively. The prescription dose
covered a median 70.4% of the PTV across all delivered
fractions. Figure 2 illustrates differences in GTV and PTV
coverage across 5 adapted fractions due to interfraction GI
OAR changes for a patient prescribed 50 Gy.
The median time from initial setup to treatment de-
livery completion was 83 minutes (range, 56-108
Table 2 Patient, tumor, and treatment characteristics
Characteristic N (range)
Total no. of patients 35












CT alone 8 (22.9%)
CT and MRI 14 (40%)
CT and PET 4 (11.4%)
CT, MRI, and PET 9 (25.7%)
Stage
Locally advanced 28 (80%)
Borderline resectable 3 (8.6%)













CA 19-9 (U/mL), median
Initial diagnosis 102.5 (0.9-1517.5)







gemcitabine alone 4 (11.4%)
none 3 (8.6%)




Total prescribed dose (Gy), median 50 (40-50)
Total prescribed fractions 5
Motion management
Breath hold 30 (85.7%)





Adapted fractions per patient, median 5 (1-5)
(continued on next page)
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minutes) for all patients. Although not statistically sig-
nificant, this was longer for the initial 17 patients
compared with the more recent 18 patients (86 vs 79.5
minutes; P Z .141) possibly reflecting our improved
proficiency with the MR-LINAC over time, which had
been operational in our department for only 6 months
when we treated the first patient in this study. Treatment
was delivered over a median 20 minutes (range, 11-36
minutes) for all patients and was similar for the initial 17
patients compared with the more recent 18 patients (20 vs
18 minutes; P Z .235) despite the transition to ENI that
resulted in large target volumes.
We recently installed a monitor in the treatment room
to show patients their real-time sagittal cine MR images
and required breath hold position throughout each frac-
tion.28 The intent was to provide visual biofeedback as a
means to decrease the number of breath holds and treat-
ment times compared with only audio coaching through
headphones, which was used for the initial 28 patients.
The median in-room time for the 9 patients treated with
versus without the monitor was 67 versus 85 minutes
(P Z .032).
Therapy after SMART
Approximately half of patients did not resume
chemotherapy after SMART (48.6%), most without
evidence of disease progression. Thirteen received
chemotherapy owing to disease progression and 5
received maintenance chemotherapy owing to medical
oncologist preference.
Three patients received irreversible electroporation
(IRE) at a median 11 months (7.3-11.1 months) after
SMART. IRE was used to manage regional progression
outside of the PTV in 2 patients; neither had distant
metastasis. A third patient with stable disease had IRE
despite lack of tumor progression, with intraoperative
biopsy before IRE being negative for invasive
adenocarcinoma.
Five patients underwent a Whipple procedure per-
formed at a median 2 months (range, 1-9 months) after
completing SMART, 3 with borderline resectable and 2
with locally advanced tumors. All resected patients
received induction FOLFIRINOX (n Z 4) or
gemcitabine/nab-paclitaxel (n Z 1). The prescribed ra-
diation dose was 50 Gy (n Z 4) or 40 Gy (n Z 1). Four
patients had negative margins and 4 had negative lymph
nodes. One had a complete response, 2 had a near com-
plete pathologic response, and 2 were noted to have a
marked pathologic response. None of these patients has
evidence of tumor recurrence after median 10.8 months
follow-up.
Tumor control and survival
Three patients had local progression although only 1
occurred within the PTV (45 Gy prescription without ENI).
The other 2 patients (50 Gy prescription with ENI for both)
progressed regionally outside of the PTV, one within a
lymph node and another along the SMA abutting the PTV.
The 1-year LC was 87.8% (95% confidence interval [CI],
79.4%-93.8%) and the median time to local progression
was 7.4 months (range, 2.5-9.8 months; Fig. 3a). Thirteen
patients developed distant metastasis after a median 3.0
months (range, 1.0-11.8 months). The 1-year distant
metastasis-free survival was 63.1% (95% CI, 55.7%-
69.5%; Fig. 3b). The 1-year PFS and median PFS were
52.4% (95% CI, 45.1%-58.2%) and 7.9 months,
Table 3 Target volume coverage reported in total dose for initial plan on simulation anatomy versus on-table adaptive plans on
daily anatomy
Target volume Initial plan on simulation anatomy (total dose) Adaptive plan on daily anatomy (total dose)
median mean  SD range median mean  SD range
PTV D90 39.8 Gy 43.9  6.3 Gy 32.7-53.0 Gy 40.5 Gy 40.9  6.0 Gy 26.8-68.1 Gy
GTV D90 50.8 Gy 50.4  6.2 Gy 38.8-58.3 Gy 47.5 Gy 47.2  5.8 Gy 32.1-68.1 Gy
PTV D80 46.2 Gy 45.9  5.6 Gy 37.4-54.9 Gy 44.7 Gy 44.7  5.4 Gy 25.6-63.3 Gy
GTV D80 52.5 Gy 51.9  4.7 Gy 44.1-58.8 Gy 49.6 Gy 50.1  4.7 Gy 39.4-69.2 Gy
PTV Max 65.9 Gy 65.2  5.7 Gy 49.9-74.1 Gy 65.7 Gy 64.9  6.1 Gy 59.8-76.1 Gy
GTV Max 65.4 Gy 61.8  4.9 Gy 57.8-73.1 Gy 65.4 Gy 64.9  6.0 Gy 59.8-76.1 Gy
PTV Mean 52.7 Gy 52.0  3.9 Gy 42.7-58.3 Gy 50.5 Gy 50.4  4.7 Gy 43.8-67.6 Gy
GTV Mean 56.3 Gy 60.3  3.4 Gy 49.4-60.1 Gy 54.4 Gy 54.0  4.0 Gy 46.9-70.8 Gy
Abbreviations: D90 Z dose to 90% of volume; GTV Z planning target volume; PTV Z planning target volume; D80 Z dose to 80% of volume; SD
Z standard deviation.
Table 2 (continued )
Characteristic N (range)
Therapy after SMART
Irreversible electroporation 3 (8.6%)
Pancreaticoduodenectomy 5 (14.3%)
Chemotherapy 18 (51.4%)
Abbreviations: CA Z cancer antigen; CT Z computed tomography;
ECOG Z Eastern Cooperative Oncology Group; FOLFIRINOX Z
5-fluorouracil, irinotecan, leucovorin, oxaliplatin; MRI Z magnetic
resonance imaging; PET Z positron emission tomography; SMART
Z stereotactic magnetic resonance image guided adaptive radiation
therapy.
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respectively (Fig. 3c). Of the 13 patient deaths, 6 were not
related to pancreas cancer: cardiac arrest (nZ 2), sepsis (n
Z 2), head trauma related to a fall (nZ 1), and pneumonia
(nZ 1). The 1-year OS and median OS were 58.9% (95%
CI, 51.6%-65.1%) and 9.8 months, respectively (Fig. 3d).
The 1-year CSS and median CSS were 77.6% (95% CI,
72.7%-84.8%) and 9.8 months, respectively (Fig. 3e).
Toxicity
Acute grade 2 toxicity (nausea, anorexia) occurred in 3
patients (8.6%). Acute grade 3 toxicity (diarrhea) was
reported in 1 patient (2.9%). One patient (2.9%) had late
grade 2 duodenal bleeding that did not require
transfusion. Late grade 3 toxicity (bile duct stenosis)
occurred in 1 patient (2.9%) without evidence of disease
progression that required percutaneous drainage. No
grade 4 to 5 events were observed.
Discussion
The proximity of OARs creates a formidable challenge
in achieving significant tumor dose intensification to
inoperable pancreas cancers and sparing especially the
stomach and bowel, as to not cause serious harm to the
patient. The importance of limiting high dose to GI
luminal organs was illustrated by the early pancreas
Figure 2 Dose-volume histograms for a patient prescribed 50 Gy that illustrates differences across 5 adapted fractions in coverage of
the (a) gross target volume and (b) planning target volume.
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stereotactic body radiation therapy (SBRT) experiences
that reported significant toxicities.29e31 For example, a
Dutch phase II trial of 45 Gy in 3 fractions (BED10 Z
112.510) that used PTV margins up to 10 mm and without
high-quality on-board CT imaging reported that 94% of
patients had at least grade 2 pain at 3 months after
treatment and multiple patients developed severe GI ul-
ceration or perforation likely because at least 67% of the
prescribed dose was delivered to the stomach or
duodenum.30 Consequently, prioritization of OAR con-
straints over target volume coverage is strongly
recommended.32
The outcomes of SBRT to 24 to 36 Gy in 3 to 5
fractions (BED10 Z 37.5-79.2 Gy10) have been modest,
although both LC and OS worsen with longer follow-up
beyond at least 1 year.33e37 For example, a phase II
trial by Quan et al of sequential gemcitabine/capecitabine
and 36 Gy in 3 fractions (BED10 79.2 Gy10) reported
Figure 3 Kaplan-Meier plots for (a) local control, (b) distant metastasis-free survival, (c) progression-free survival, (d) overall sur-
vival, and (e) cause-specific survival.
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1-year LC and OS of 78% and 54% although 2-year LC
and OS decreased to 52% and 10%, respectively, among
nonsurgical patients.
There has recently become greater enthusiasm in ra-
diation dose escalation for inoperable pancreas cancer to
potentially improve clinical outcomes.4e8,10,17 In-
vestigators from MD Anderson Cancer Center reported
that LAPC patients, typically treated in 28 fractions with
daily CT guidance, had higher median survival (17.8 vs
15.0 months; P Z .03) and local-regional relapse free
survival (10.2 vs 6.2 months; P Z .05) when a biologi-
cally effective dose (BED10) >70 Gy10 was prescribed
(Table 4).4 Dose intensification was considered, typically
with fractionation over multiple weeks to mitigate
toxicity, if there was 1 cm between tumor and luminal
GI structures. This is uncommon and highlights the need
Figure 3 (continued.)
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for technologies that can safely achieve dose escalation
for a broader population.
MRgRT is a novel technique that facilitates dose
escalation in the abdomen beyond what has been histor-
ically feasible using CT.5,17,22,38 SMART delivered with
Co-60 was tolerated remarkably well in an analysis by
Rudra et al of 44 pancreas patients, with 25 receiving dose
escalation to 40 to 67.5 Gy over 5 to 15 fractions.5 The
minority received 5 fractions although it was not specified
how many received at least 50 Gy (BED10 100 Gy10); it
was likely a small number given the median prescribed
BED10 was 77.6 Gy10. Similar to the MD Anderson
Cancer Center analysis, BED10 >70 Gy10 was associated
with improved outcomes. Earlier this year, a retrospective
analysis of SMART prescribed to 50 Gy in 5 fractions
without ENI was published by investigators at Washing-
ton University in St. Louis that included 44 inoperable
pancreas cancer patients, most (86%) treated on a Co-60
system.17 With median follow-up of 16 months from
pancreas cancer diagnosis, outcomes included 2-year LC,
PFS, and OS of 59.3%, 13.9%, and 37.9%, respectively.
Treatment was very well tolerated with limited grade 3
toxicity.
To the best of our knowledge the present study rep-
resents the first reported outcomes of ablative 5-fraction
pancreas SMART delivered only on an MR-LINAC. With
median follow-up of 10.3 months from SMART our early
outcomes are encouraging. Although we cannot draw
conclusions about the effect of ENI on our 1-year LC of
87.8%, which is encouraging compared with other stud-
ies,4,34e37 it is notable that only 1 patient had disease
progression within the PTV, and the others progressed
regionally outside of the PTV. Furthermore, the use of
ENI was not associated with significant toxicity.
Although our 1-year OS of 58.9% is similar to other
pancreas SBRT studies that prescribed nonablative doses,
nearly half of deaths were not related to pancreas cancer
or to treatment-related toxicity. Lastly, grade 3 toxicity
occurred in only 2 patients, which likely was achieved by
interfraction anatomic changes being visualized daily on
MRI and on-table adaptive replanning being able to ac-
count for these changes.
There are several aspects of our treatment approach
worth emphasizing. First, there was no need to refer pa-
tients for fiducial marker placement, which could other-
wise delay simulation up to several weeks. There was
only a median 1 day between consultation to simulation
and a median 13 days from consultation to delivery of
first fraction for patients in our study. Whether decreasing
the interval to start of RT effects long-term outcomes
remains unknown; in the short-term this can mitigate
patient anxiety especially because some patients are
referred for RT with local progression while on chemo-
therapy. Second, treatment was delivered in consecutive
days and we did not prescribe a prophylactic proton pump
inhibitor. Third, continuous intrafraction tissue tracking
permitted breath hold delivery, eliminating the need for an
internal target volume and thereby reducing the volume of
normal tissue exposed to high dose. Direct intrafraction
visualization of the tumor and in-plane OARs abutting the
high dose gradient enabled not only greater confidence
throughout the ablative dose delivery, but also allowed for
treatment halting and repeat 3-dimensional MRI to adjust
for the intrafraction motion detected on 2-dimensional
Figure 3 (continued.)
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MRI. The need for intrafraction dose assessment and
reoptimization is currently unclear and this should be
explored in future studies.28 Fourth, we found that both
tumor and normal anatomy are visualized well on the MR
simulation and daily treatment breath hold scans without
contrast. This has improved patient satisfaction by
avoiding diarrhea, the need to check renal function, and
obtain intravenous access. We have also been able to free
up nursing resources and decrease the time needed on the
CT simulator for these patients. Fifth, most patients were
treated to elective nodal regions, which is unconventional
and frankly controversial.6,9,25 The role of ENI remains
debated and owing to potentially severe toxicity, at least
using CT image guidance, some have recommended
against it.11 Electively treated regions typically received
an ablative dose prescription, and although this was
tolerated well the long-term effects of this need to be
closely evaluated. Lastly, ablative dose covered most of
the targets as demonstrated by the median GTV and PTV
D80 and D90 on the initial plans. Despite the need to adapt
most fractions we were able to maintain ablative dose to
most of the GTV and PTV, respectively. This is in distinct
contrast to the strategy commonly used for low dose
SBRT using daily CT guidance in which dose escalation
is confined to a restricted volume, for example only the
tumor-vessel interface.9,35,39,40
Study limitations include that this is a retrospective
analysis and subject to underreporting of toxicities
although toxicities were evaluated prospectively at the
time of each patient encounter. Patient numbers are small,
although are similar to most published prospective or
retrospective pancreas SBRT studies. Our results would
benefit from more extended follow-up to better under-
stand late toxicity and long-term clinical outcomes. Still,
we believe that our median follow-up of 10.3 months is
long enough to provide meaningful comparison to other
studies, especially given that the median survival for
LAPC patients is approximately 12 to 16 months.4 In
addition, whereas other analyses with longer follow-up
measured outcomes from the time of diagnosis,17,36
which then is routinely followed by at least several
months of chemotherapy, our analysis began from the
initiation of SMART. Lastly, although most fractions
were adapted the cumulative dose was not assessed with
respect to clinical outcomes.
Conclusions
In conclusion, 50 Gy in 5 consecutive fractions
delivered using an MR-LINAC to inoperable pancreas
cancer and elective nodal regions with daily on-table
adaptive replanning can achieve excellent early LC and
with limited severe toxicity. Our experience supports
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ablative SMART prescribed to 50 Gy in 5 fractions
(NCT03621644).
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